Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
View original at finance.yahoo.comProtagonist Therapeutics Announces U.S…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Rates of adverse reactions for ICOTYDE treated patients were within 1.1% of placebo through Week 16 and no new safety signals were identified through Week 52
60% confidenceTransition to systemic therapy is recommended if two cycles of topical medications applied for four weeks fail to bring meaningful improvement
60% confidenceWith the pending FDA decision for rusfertide this year, and the financial resources for accelerating pipeline investment, this is the beginning of a multi-year product-driven growth cycle for Protagonist Therapeutics
60% confidenceApproximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved a PASI90 response at Week 16 in head-to-head studies
60% confidenceNearly one-quarter of all people with plaque psoriasis have cases that are considered moderate to severe
60% confidenceApproximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved PASI90 response at Week 16 in head-to-head studies
60% confidencePsoriasis affects more than eight million Americans
60% confidenceICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance
60% confidenceMore than 125 million people worldwide live with plaque psoriasis
60% confidenceThe FDA approval of ICOTYDE demonstrates the strength of Protagonist's peptide technology platform to generate innovative therapies
60% confidenceThe FDA approval of ICOTYDE demonstrates the strength of Protagonist's peptide technology platform to generate innovative therapies
60% confidenceICOTYDE offers a novel plaque psoriasis treatment that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill
60% confidenceTransition to systemic therapy is recommended if two cycles of topical medications applied for four weeks fail to bring meaningful improvement
60% confidenceICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill
60% confidenceMore than 125 million people worldwide live with plaque psoriasis
60% confidenceRates of adverse reactions for ICOTYDE treated patients were within 1.1% of placebo through Week 16 and no new safety signals were identified through Week 52
60% confidenceThis is the beginning of a multi-year product-driven growth cycle for Protagonist Therapeutics
60% confidenceNearly one-quarter of all people with plaque psoriasis have cases that are considered moderate to severe
60% confidencePsoriasis affects more than eight million Americans
60% confidenceICOTYDE offers a novel plaque psoriasis treatment that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill
60% confidence